Virology / vaccines

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna.   mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase II clinical trial being […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new […]

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business.   Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a 4% year-on-growth at CER.   The quarterly results are […]

Sekkei Bio, an India-based company dedicated to building technologies for drug and vaccine design with global impact, has implemented CDD Vault as the main platform to house its research data.   Sekkei Bio has made progress toward finding therapies for diabetes and pain, and has a management team with a track record of successfully bringing drugs […]

Allison August, M.D., Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need.  Although cytomegalovirus (CMV) is almost ubiquitous in the adult population globally, it is an under-recognised infectious cause of […]

DDW Editor Reece Armstrong takes a look at the recent Covid-19 patent battles involving key players in the pharmaceutical sector.  There’s no doubting that when the time came for the life sciences industry to step up during the Covid-19 pandemic, it delivered. From diagnostics to PPE and eventually the launch of Covid-19 vaccines – within a never-before-seen […]

A monoclonal antibody (mAb) treatment for the prevention of Malaria has shown encouraging results in a US Phase I clinical trial.   The mAb, known as L9LS, was developed by scientists at the National Institutes of Health’s (NIH) Vaccine Research Centre (VRC). L9LS is a laboratory-made version of a naturally occurring antibody called L9, developed from […]

News round-up by DDW’s Reece Armstrong for 8-12 August  New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine    Pfizer has launched a Phase III clinical trial of a vaccine to […]

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva.   The Vaccine Against Lyme for Outdoor Recreationists (VALOR) trial will investigate the efficacy, safety and immunogenicity of Pfizer and Valneva’s Lyme disease vaccine candidate, VLA15.   The trial will enrol up to 6,000 […]

Researchers from the University of Oxford have today reported new findings from a Phase I clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG. The RAB001 trial was conducted at the University and is the first time the novel rabies vaccine has been used in human volunteers. […]